
16/02/2025
Carbetosine, a Long-acting Oxytocin Agonist, as a Uterotonic in the Prevention of the Occurrence of Postpartum Bleeding
Discussion :
Our current meta-analysis compared the effectiveness of carbetocin as a uterotonic drug in reducing the risk of postpartum hemorrhage. Patients administered carbetocin exhibit a significantly lower risk of bleeding compared to those receiving other uterotonic treatments. Previous research involved a comparison between carbetocin and oxytocin to prevent postpartum hemorrhages. This study revealed that carbetocin reduced the necessity for uterotonics particularly those who underwent cesarean deliveries. However, vaginal delivery did not yield the same outcomes. The study found no significant difference between using carbetocin, oxytocin, or another control in terms of reducing the risk of postpartum hemorrhage, which is defined as any blood loss greater than 500 ml, or the threat of severe PPH, which is defined as a condition of blood loss greater than 1000 ml.